Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study

Posted on 15 November 2018 | Posted by Gregory G. Schwartz | Posted in Videos, American Heart Association Scientific Sessions 2018

Latest videos

Frederick J. Raal Lerodalcibep: What does LIBerate-HeFH tell us?

Steve Humphries Verve-101: Where are we up to with PCSK9 gene editing?

Marianna Pavlyha Apo(a) size and PAD revascularisation outcomes: What’s the link?

Steve Nissen Lepodisiran: What progress towards Lp(a) reduction?

« Back to videos

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters